SAB Biotherapeutics Inc.

NASDAQ: SABS · Real-Time Price · USD
2.19
-0.02 (-0.90%)
At close: Aug 15, 2025, 3:59 PM
2.21
0.91%
After-hours: Aug 15, 2025, 07:52 PM EDT

SAB Biotherapeutics Balance Sheet Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Cash & Equivalents
8.9M 56.57M 15.05M 33.21M
Short-Term Investments
11.86M n/a n/a n/a
Long-Term Investments
n/a n/a n/a n/a
Other Long-Term Assets
482.1K 350.23K 467.69K n/a
Receivables
54.95K n/a 5.56M 8.01M
Inventory
n/a n/a n/a n/a
Other Current Assets
2.98M n/a n/a 6.34M
Total Current Assets
23.79M 58.91M 22.1M 50.19M
Property-Plant & Equipment
19.92M 24.68M 28.34M 30.95M
Goodwill & Intangibles
n/a n/a n/a n/a
Total Long-Term Assets
20.4M 25.03M 28.81M 30.95M
Total Assets
44.2M 83.94M 50.9M 79.37M
Account Payables
1.69M 945.93K 3.68M 4.46M
Deferred Revenue
n/a 1.32M n/a 100K
Short-Term Debt
811.84K 1.05M 772.66K 1.8M
Other Current Liabilities
5.47M 4.49M 8.1M 13.99M
Total Current Liabilities
7.98M 10.81M 14.99M 24.68M
Long-Term Debt
n/a n/a 541.64K n/a
Other Long-Term Liabilities
6.39M 11.77M 320.93K 10.72M
Total Long-Term Liabilities
10.25M 15.83M 4.85M 16.14M
Total Liabilities
18.23M 26.64M 19.85M 40.82M
Total Debt
4.67M 5.91M 5.93M 8.52M
Common Stock
935.00 929.00 5.09K 4.35K
Retained Earnings
-124.17M -90.06M -47.87M -29.13M
Comprehensive Income
-135.41K 26.42K n/a n/a
Shareholders Equity
25.97M 57.3M 31.06M 38.55M
Total Investments
11.86M n/a n/a n/a